[{"data": {"name": "CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "T.K. Choueiri", "@type": "Person"}, {"name": "S. Halabi", "@type": "Person"}, {"name": "B. Sanford", "@type": "Person"}, {"name": "O. Hahn", "@type": "Person"}, {"name": "M.D. Michaelson", "@type": "Person"}, {"name": "M. Walsh", "@type": "Person"}, {"name": "T. Olencki", "@type": "Person"}, {"name": "J. Picus", "@type": "Person"}, {"name": "E.J. Small", "@type": "Person"}, {"name": "S. Dakhil", "@type": "Person"}, {"name": "D. George", "@type": "Person"}, {"name": "M.J. Morris", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://academic.oup.com/annonc/article-pdf/27/suppl_6/LBA30_PR/19452308/mdw435.23.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Oxford University Press (OUP)", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1093/annonc/mdw435.23", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCLUf3SVN8pUV-CTL78fTE4qpz5-CD9ju3J8L9T98-CRfwnRHDoR9Av", "propertyID": "ISCC"}], "datePublished": "2016-10-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]